Nodes Logo
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

NeoImmuneTech

T cell-focused novel immuno-therapeutics

| Overview |

With a lead asset NT-I7 (efineptakin alfa) that promotes T cell development and amplification, NeoImmuneTech is a clinical-stage, publicly traded immunology company with indications in oncology, hematology, and infectious disease.

Sector

Therapeutics

Round

PIPE

Transaction

Capital Raise

Transaction Value

Undisclosed

Space

Immunology, Oncology, Hematology, and Infectious disease

Milestones

  • Founded in 2014
  • Listed on the KOSDAQ in 2021
  • Granted ODD from FDA for NT-I7 in the treatment of ARS in 2023

Investors

Founders

Se Hwan Yang, Ph.D.

Challenge

Expanding the Horizon of Immuno-Oncology

NeoImmuneTech is expanding the horizon of Immuno-Oncology and enhancing immunity to infectious diseases.

Solution

Diverse pipeline spanning multiple oncologic and lymphopenia-related indications

NIT's long-acting IL-7 therapeutics demonstrate safety and preliminary efficacy in ongoing Phase I and II oncology trials, with promising results in non-oncology pipelines. This includes NT-I7 mono therapy, as well as combination therapies with checkpoint inhibitors and CAR-T cells.

Impact

Addressing unmet medical needs caused by local or systemic T cell depletion

Unlike other cytokines, Interleukin-7 (IL-7) induces selective expansion of T cells to restore a core component of the immune response. Other T cell–promoting cytokines such as IL-2 and IL-15 only support T cell differentiation, activation, and/or proliferation without driving new development—and they cause cytokine storm when given clinically.

At present, with major clinical trials examining solid tumors, brain cancer, and blood cancer progressing smoothly, we plan to maximize the value of new drug development for the next generation immunotherapy, to be acknowledged by the global market, by giving our best efforts in clinical development and continuing to communicate with the market.

Se Hwan Yang CEO & President NeoImmuneTech, Inc.

| In the News |

No items found.

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.